Business
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"text","content":"Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode of action differentiated from standard of care treatment WASHINGTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced the journal, New Microbes and New Infections, has published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity, including against Candida spp. in cell culture, and decreases fungal burden in the lungs in an invasive pulmonary model of Rhizopus in mice. New Microbes and New Infections is a peer-reviewed, open-access journal. The research was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Tafenoquine is the active ingredient in an anti-malarial approved by the FDA in 2018 and is indicated for the prophylaxis of malaria in patients aged 18 years of age and older. 60P was recently awarded a U.S. patent covering tafenoquine for treatment of COVID-19 and other lung infections. “A substantial unmet need exists for clinical therapies that treat and prevent life-threatening fungal infections,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow. “Even when antifungal treatments approved by the FDA are administered to patients, the morbidity, mortality, and clinical incidence of rapidly emerging, dangerous fungal infections such as Candida and Rhizopus remain high. Data from this set of studies confirm that tafenoquine holds promise in addressing that unmet need in the U.S. It is particularly interesting that tafenoquine did not exhibit any cross-resistance to fluconazole against Candida species, and that the presumed mode of action, through the induction of oxidative stress, differs from standard of care treatments. We are pursuing this hypothesis as part of our research strategy.” About Candida auris (C. auris) and Rhizopus Candida auris (C. auris) is an emerging fungus that presents a serious global health threat, according to the Centers for Disease Control and Prevention (CDC). C. auris is often multi-drug-resistant, meaning that it is resistant to mult...